EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY 4.0

Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial

Thomas R Pieber, Kristine N Arfelt, Roman Cailleteau, Marlies Hart, Soumitra Kar, Ines Mursic, Eva Svehlikova, Martina Urschitz, Hanne Haahr

Diabetologia · 2023

DOI: 10.1007/s00125-023-05921-8 ↗

At a glance

Randomisierte kontrollierte Studie in Diabetologia, 2023. Written by Thomas R Pieber and 8 co-authors. Institution: Department of Internal Medicine, Medical University of Graz, Graz, Austria. thomas.pieber@medunigraz.at. Major MEDLINE topics: Diabetes Mellitus, Type 2, Hypoglycemia. Cited 21 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: Novo Nordisk A/S, Medical University of Graz.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims/hypothesis This study compared the frequency of hypoglycaemia, time to hypoglycaemia and recovery from hypoglycaemia after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100. Furthermore, the symptomatic and counterregulatory responses to hypoglycaemia were compared between icodec and glargine U100 treatment.

Methods

In a randomised, single-centre (Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria), open-label, two-period crossover trial, individuals with type 2 diabetes (age 18–72 years, BMI 18.5–37.9 kg/m 2 , HbA 1c ≤75 mmol/mol [≤9.0%]) treated with basal insulin with or without oral glucose-lowering drugs received once-weekly icodec (for 6 weeks) and once-daily glargine U100 (for 11 days). Total weekly doses were equimolar based on individual titration of daily glargine U100 during the run-in period (target fasting plasma glucose [PG]: 4.4–7.2 mmol/l). Randomisation was carried out by assigning a randomisation number to each participant in ascending order, which encoded to one of two treatment sequences via a randomisation list prepared prior to the start of the trial. At steady state, double and triple doses of icodec and glargine U100 were administered followed by hypoglycaemia induction: first, euglycaemia was maintained at 5.5 mmol/l by variable i.v. infusion of glucose; glucose infusion was then terminated, allowing PG to decrease to no less than 2.5 mmol/l (target PG nadir ). The PG nadir was maintained for 15 min. Euglycaemia was restored by constant i.v. glucose (5.5 mg kg −1 min −1 ). Hypoglycaemic symptoms score (HSS), counterregulatory hormones, vital signs and cognitive function were assessed at predefined PG levels towards the PG nadir .

Results

Hypoglycaemia induction was initiated in 43 and 42 participants after double dose of icodec and glargine U100, respectively, and in 38 and 40 participants after triple doses, respectively. Clinically significant hypoglycaemia, defined as PG nadir

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2HypoglycemiaHumansAdolescentYoung AdultAdultMiddle AgedAgedInsulin GlargineCross-Over StudiesHydrocortisoneHypoglycemic AgentsInsulinGlucoseEpinephrineBlood GlucoseInsulin, Long-Acting

Author keywords

Cognitive functionCounterregulationHypoglycaemiaHypoglycaemia awarenessHypoglycaemic symptomsInsulin glargine U100Insulin icodecOnce-weeklyPharmacokineticsType 2 diabetes

Substances

Insulin GlargineHydrocortisoneHypoglycemic AgentsInsulinGlucoseEpinephrineBlood Glucoseinsulin icodecInsulin, Long-Acting

Authors and institutions

  • Department of Internal Medicine, Medical University of Graz, Graz, Austria. thomas.pieber@medunigraz.at.
  • Novo Nordisk A/S, Søborg, Denmark.
  • Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Novo Nordisk Service Centre India Private Ltd., Bangalore, India.

Funding

  • Novo Nordisk A/S
  • Medical University of Graz

Cite

APA

Pieber, T. R., Arfelt, K. N., Cailleteau, R., Hart, M., Kar, S., Mursic, I., Svehlikova, E., Urschitz, M., & Haahr, H. (2023). Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial. Diabetologia. https://doi.org/10.1007/s00125-023-05921-8

Vancouver

Pieber TR, Arfelt KN, Cailleteau R, Hart M, Kar S, Mursic I, et al. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial. Diabetologia. 2023. doi:10.1007/s00125-023-05921-8

BibTeX
@article{Pieber2023,
  author = {Pieber, Thomas R and Arfelt, Kristine N and Cailleteau, Roman and Hart, Marlies and Kar, Soumitra and Mursic, Ines and Svehlikova, Eva and Urschitz, Martina and Haahr, Hanne},
  title = {Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial},
  journal = {Diabetologia},
  year = {2023},
  doi = {10.1007/s00125-023-05921-8}
}
Start for free →